Bone Marrow Transplantation最新文献

{"title":"Reduced-intensity T-replete allogeneic stem cell transplantation provides long-term survival in relapsed angioimmunoblastic T-cell lymphoma post-autologous transplant in patients over the age of 50.","authors":"Ioannis Arvanitis, Cristina Maschio, Dimitrios Panaretos, Julieta Osorio Zuluaga, Faraz Khan, Mariam Alamin, Charmaine Campbell, Nabeel Bader, Alexandros Kanellopoulos, Emmanouil Nikolousis","doi":"10.1038/s41409-026-03037-2","DOIUrl":"https://doi.org/10.1038/s41409-026-03037-2","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149029740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transplant-associated thrombotic microangiopathy in children treated with allogeneic hematopoietic stem cell transplantation.","authors":"Tomasz Jarmoliński, Monika Rosa, Iwona Bil-Lula, Joanna Korlaga, Krzysztof Kujawa, Marek Ussowicz, Krzysztof Kałwak","doi":"10.1038/s41409-026-03042-5","DOIUrl":"https://doi.org/10.1038/s41409-026-03042-5","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FLT3 inhibitor maintenance after allogeneic transplantation is associated with improved survival in FLT3-mutated AML: MRD-stratified evidence from an updated meta-analysis.","authors":"Abdulrahim Mohammed Basendwah, Akihiro Miyashita, Henri Fero, Mohammed Alasmari, Fahad Alabbas","doi":"10.1038/s41409-026-03049-y","DOIUrl":"https://doi.org/10.1038/s41409-026-03049-y","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149015537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world utilization of thrombopoietin receptor agonists in the italian hematopoietic stem cell transplantation setting: a comprehensive national survey by the Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO).","authors":"Gianluca Martini, Luca Castagna, Michele Malagola, Mattia Algeri, Anna Colpo, Valentina De Cecco, Claudia Del Fante, Nicoletta Sacchi, Stella Santarone, Marco Zecca, Antonio Bianchessi, Irene Defrancesco, Caterina Zerbi, Martina Pitea, Eliana Degrandi, Nicola Polverelli, Massimo Martino","doi":"10.1038/s41409-026-03045-2","DOIUrl":"https://doi.org/10.1038/s41409-026-03045-2","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149001242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GVHD prophylaxis and incidence in contemporary alloHSCT: a large real-world GETH/TC analysis.","authors":"Carmen Martínez, Leyre Bento, María Queralt Salas, Juan Montoro, Jaime Sanz, Lucia López Corral, Estefanía Pérez López, María Jesús Pascual, Irene García-Cadenas, María Suarez-Lledó, Arancha Bermúdez, Felipe Peña, Carlos Carretero, María-José Jiménez Lorenzo, Pedro Antonio González-Sierra, Antonia Sampol, Inmaculada Heras, Teresa Zudaire, Silvia Filaferro, Ángel Cedillo, Pascual Balsalobre, Carlos Solano, Manuel Jurado","doi":"10.1038/s41409-026-03035-4","DOIUrl":"https://doi.org/10.1038/s41409-026-03035-4","url":null,"abstract":"<p><p>Graft-versus-host disease (GVHD) remains a major limitation of allogeneic hematopoietic stem cell transplantation (alloHSCT) outcomes. The increasing use of post-transplant cyclophosphamide (PTCy) and antithymocyte globulin (ATG) has expanded beyond haploidentical transplantation to matched related (MRD) and unrelated donor (MUD) settings, although real-world GVHD incidence in this context is not well characterized. We performed a nationwide retrospective study including 1544 alloHSCTs conducted in Spain between 2018 and 2020. PTCy-based prophylaxis was used in 65.6% of transplants, being almost universal in haploidentical procedures (96.9%) and predominant in mismatched donors (72.4%), with notable use in MRD (43.5%) and MUD (56.8%). The cumulative incidence of grade II-IV acute GVHD at day +100 and 1 year was 28.4% and 30.7%, respectively, while grade III-IV occurred in 6.9% and 8.0%. Despite the prevalent use of peripheral blood stem cells, chronic GVHD at 2 years was 36.7%, with 23.5% moderate-to-severe. Acute GVHD was strongly associated with inferior survival (HR 2.40; P < 0.001), particularly grade III-IV disease (HR 4.34; P < 0.001). This large nationwide real-world study highlights the shift in GVHD prophylaxis in modern alloHSCT and underscores the need to define new studies based on this evolving landscape.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Azacitidine maintenance after allogeneic hematopoietic stem cell transplantation in high-risk AML: a single-center retrospective study.","authors":"Federica Ardizzoia, Francesco Iannotta, Francesco De Felice, Margherita Ursi, Francesco Barbato, Marcello Roberto, Gabriele Fontana, Michele Loffredo, Sadia Falcioni, Enrica Tomassini, Barbara Sinigaglia, Luca Zazzeroni, Elisa Dan, Elena Campanini, Daria Messelodi, Salvatore Nicola Bertuccio, Maria Naddeo, Irene Salamon, Serena De Matteis, Francesca Ricci, Gianluca Storci, Massimiliano Bonafè, Enrico Maffini, Francesca Bonifazi","doi":"10.1038/s41409-026-02998-8","DOIUrl":"https://doi.org/10.1038/s41409-026-02998-8","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148966340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS.","authors":"Tereza Coman, Stéphane Morisset, Raynier Devillier, Maud D'Aveni, Frederic Baron, Jacques Olivier Bay, Jean El-Cheikh, Karine Bilger, Claude-Eric Bulabois, Cristina Castilla-Llorente, Patrice Ceballos, Yves Chalandon, Sylvain Chantepie, Magalie Joris, Patrice Chevallier, Mustafa Alani, Jerôme Cornillon, Etienne Daguindeau, Edouard Forcade, Chama Mokeddem, Gaelle Guillerm, Hélène Labussiere, Philippe Lewalle, Mikael Loschi, Johan Maertens, Florent Malard, Jean-Valère Malfuson, Natacha Maillard, Jean Baptiste Mear, Stéphanie Nguyen-Quoc, Cécile Pivert, Xavier Poire, Marie-Thérèse Rubio, Felipe Suarez, Pascal Turlure, Alban Villate, Ibrahim Yakoub-Agha, Nicole Raus, Marie Robin, Anne Huynh, Mauricette Michallet","doi":"10.1038/s41409-026-03033-6","DOIUrl":"https://doi.org/10.1038/s41409-026-03033-6","url":null,"abstract":"<p><p>Post-transplant cyclophosphamide (PTCy) has transformed graft-versus-host disease (GVHD) prophylaxis but its role in matched-donor reduced-intensity allogeneic hematopoietic cell transplantation (allo-HCT) remains uncertain. We retrospectively analyzed adults with AML or MDS reported to the French-Belgian-Swiss EBMT/SFGM-TC registry who received a first allo-HCT from a matched related (MRD) or matched unrelated donor (MUD) after reduced-intensity conditioning (RIC) with peripheral blood stem cells between 2014 and 2022. Among 3624 patients, GVHD prophylaxis comprised immunosuppressive agents without in vivo T cell depletion (NONE, n = 213), PTCy±immunosuppression (PTCy, n = 97), ATG±immunosuppression (ATG, n = 3 286), or PTCy+ATG±immunosuppression (PTCy+ATG, n = 28). In multivariable competing-risk models, PTCy was associated with a significant reduction of grade III-IV aGVHD compared to ATG (HR 0.44, p = 0.026). Both PTCy and ATG were associated with a lower incidence of extensive cGVHD vs NONE, without affecting NRM or relapse risk. With a median follow up of 16.6 months, the probability of 1-year OS, PFS and GRFS were 69.92%, 62.46% and 48.39%, regardless of donor type or GVHD prophylaxis group. These large, homogeneous registry data support PTCy as an effective alternative to ATG for GVHD prophylaxis in RIC MRD/MUD allo-HCT for AML/MDS, and provide a benchmark while ongoing randomized trials mature.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148954722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of GvHD prophylaxis regimens based on in vivo T-cell depletion (ATG vs. alemtuzumab) in patients with AML undergoing allo-HCT from unrelated donors with intermediate transplant conditioning intensity protocols: a registry study on behalf of the EBMT acute leukemia working party.","authors":"Jesús Duque-Afonso, Jürgen Finke, Allain-Thibeault Ferhat, Jacques-Emmanuel Galimard, Francesca Kinsella, Deborah Richardson, Friedrich Stölzel, Eleni Tholouli, Caroline Besley, Matthias Eder, Emma Nicholson, Robert Zeiser, Adrian Bloor, Charles Crawley, Katherine Clesham, Jennifer Byrne, Patrick Medd, Elisa Sala, Caroline Pabst, Jan Vydra, Eva Maria Wagner-Drouet, Alain Gadisseur, Alexandros Spyridonidis, Eolia Brissot, Arnon Nagler, Mohamad Mohty, Fabio Ciceri","doi":"10.1038/s41409-026-03016-7","DOIUrl":"10.1038/s41409-026-03016-7","url":null,"abstract":"<p><p>Allogeneic hematopoietic cell transplantation is a potentially curative therapy for acute myeloid leukemia (AML), but its success is limited by graft-versus-host disease (GvHD). Optimal in vivo T-cell depletion strategies for GvHD prophylaxis given with conditioning regimens remain under investigation. We compared antithymocyte globulin (ATG) and alemtuzumab as GvHD prophylaxis in adult AML patients in complete remission (CR1/CR2) undergoing allogeneic cell transplantation from unrelated-donors conditioned with intermediate-intensity regimens. From the EBMT registry, 1545 patients were identified (710 ATG; 835 alemtuzumab). Patients receiving ATG were slightly older and had higher comorbidity scores, but groups were otherwise comparable. At 3 years, ATG was associated with superior overall survival (58.3% vs. 50.4%, p = 0.03) and leukemia-free survival (52.1% vs. 45.7%, p = 0.014). ATG recipients also demonstrated significantly lower relapse incidence (21.9% vs. 28.1%, p = 0.006), while non-relapse mortality remained similar between groups (26% vs. 26.3%, p = 0.46). Although ATG was associated with a higher incidence of acute GvHD, chronic GvHD rates did not differ significantly. In summary, for AML patients in complete remission receiving intermediate-intensity conditioning, ATG improved long-term survival and reduced relapse risk compared with alemtuzumab, despite increased acute GvHD. These findings support ATG as an effective GvHD prophylactic option in this setting.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148928930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early deterioration and subsequent recovery of nursing complexity after CAR-T therapy: a prospective score-based analysis.","authors":"Eugenio Galli, Ilaria Pansini, Elisabetta Schifitto, Alessandro Corrente, Pasquale Rea, Giorgia Brizzi, Alessio Capitani, Teresa Laviano, Fabio Lamberti, Cinzia Sechi, Marco Cioce, Elisabetta Metafuni, Sabrina Giammarco, Federica Sorà, Patrizia Chiusolo, Simona Sica","doi":"10.1038/s41409-026-03031-8","DOIUrl":"https://doi.org/10.1038/s41409-026-03031-8","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148896579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation.","authors":"Martina Reuss, Thomas Meyer, Florian Ingelfinger, Rouven Hoefflin, Miriam Mozaffari Jovein, Hosna Baniadam, Dietmar Pfeifer, Justus Duyster, Jesus Duque-Afonso, Kristina Maas-Bauer, Ralph Wäsch, Armin Zebisch, Annkristin Heine, Tobias Holderried, Jürgen Finke, Claudia Wehr, Robert Zeiser, Tobias Wertheimer","doi":"10.1038/s41409-026-03029-2","DOIUrl":"https://doi.org/10.1038/s41409-026-03029-2","url":null,"abstract":"<p><p>TP53 mutations define a clinically distinct subset of acute myeloid leukaemia (AML) associated with complex cytogenetics and therapy resistance. We performed a retrospective single-centre analysis of 61 consecutive TP53-altered AML patients undergoing first allogeneic haematopoietic cell transplantation (allo-HCT) at the Medical Center Freiburg (2007-2025), compared with 636 TP53-wild-type controls. TP53-altered patients had markedly inferior overall survival (median 379 vs. 1694 days; 5-year OS 18% vs. 50%; p < 0.001). Excess relapse was the primary driver (5-year cumulative incidence 55% vs. 33%; p < 0.001), whereas non-relapse mortality did not differ (28.5% vs. 23%; p = 0.426). On multivariable Cox analysis, TP53 alteration was the strongest independent predictor of inferior OS (HR 2.54, 95% CI 1.77-3.64; p < 0.001), and this association persisted after adjustment for cytogenetic risk and for the refined Disease Risk Index. In an exploratory hierarchical clustering analysis extended by seven patients from a second centre, two subgroups emerged: a del(17p)-enriched cluster (n = 12; median OS 5.7 months) and a TP53 point mutation-enriched cluster (n = 56; median OS 15.1 months). TP53-altered AML is confirmed as the strongest independent adverse prognostic factor after allo-HCT, and molecular heterogeneity within this subtype may inform trial stratification and targeted post-transplant interventions.</p>","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":" ","pages":""},"PeriodicalIF":5.1,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}